Quarterly ResultSep 28, 2026, 07:16 AM
Inventiva H1 2026 Net Loss €69.5M; Refinancing Completed
AI Summary
Inventiva S.A. reported its financial results for the first half of 2026, showing a reduced net loss of €69.5 million compared to €175.9 million in the prior year period. Revenues significantly decreased to €20 thousand from €4.5 million. The company also detailed a comprehensive refinancing transaction completed in June 2026, which included an equity offering and debt financing, and expects this to fund operations until the end of Q2 2027. Key clinical trial updates include the expectation of topline results for the Phase 3 NATiV3 trial in Q4 2026.
Key Highlights
- Inventiva reported a net loss of €69.5 million for H1 2026, compared to €175.9 million in H1 2025.
- Revenues for H1 2026 were €20 thousand, a significant decrease from €4.5 million in H1 2025.
- R&D expenses increased to €46.2 million in H1 2026 from €44.9 million in H1 2025.
- General and administrative expenses rose to €22.2 million in H1 2026 from €14.7 million in H1 2025.
- Inventiva completed a comprehensive refinancing transaction in June 2026, including an Equity Offering and Debt Financing.
- The company expects to finance operations until the end of Q2 2027 based on current cash and proceeds from refinancing.
- Topline results for the Phase 3 NATiV3 clinical trial are expected in Q4 2026.
Price Impact
More from IVA